Xconomy | Seattle - Business + Technology in the Exponential Economy

Biotech, Life Sciences, Regenerative Medicine

CellCyte Settles SEC Investigation

Luke Timmerman 5/18/09

CellCyte Genetics, the Bothell, WA-based biotech company, has tentatively agreed to a settlement of a yearlong investigation by the Securities and Exchange Commission. The company entered a consent decree in which it will neither admit nor deny any wrongdoing, according to its annual report. The company hasn’t disclosed the nature of the investigation, although its stock price briefly topped $7 in December 2007, and now is worth six cents, according to this report in The Seattle Times.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.


Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.